712 related articles for article (PubMed ID: 23269308)
1. Neopterin concentration as an index of disease activity in Crohn's disease and ulcerative colitis.
Husain N; Tokoro K; Popov JM; Naides SJ; Kwasny MJ; Buchman AL
J Clin Gastroenterol; 2013 Mar; 47(3):246-51. PubMed ID: 23269308
[TBL] [Abstract][Full Text] [Related]
2. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease.
Winterkamp S; Weidenhiller M; Otte P; Stolper J; Schwab D; Hahn EG; Raithel M
Am J Gastroenterol; 2002 Dec; 97(12):3071-7. PubMed ID: 12492192
[TBL] [Abstract][Full Text] [Related]
3. Plasma citrulline concentration as a marker for disease activity in patients with Crohn's disease.
Elkhatib I; Buchman AL
J Clin Gastroenterol; 2012 Apr; 46(4):308-10. PubMed ID: 21897281
[TBL] [Abstract][Full Text] [Related]
4. [Neopterin in assessing the activity of inflammatory bowel diseases: ulcerative colitis and Crohn's disease].
Ciećko-Michalska I; Fedak D; Mach T
Przegl Lek; 2010; 67(12):1262-5. PubMed ID: 21591350
[TBL] [Abstract][Full Text] [Related]
5. Neopterin is a novel reliable fecal marker as accurate as calprotectin for predicting endoscopic disease activity in patients with inflammatory bowel diseases.
Nancey S; Boschetti G; Moussata D; Cotte E; Peyras J; Cuerq C; Haybrard J; Charlois AL; Mialon A; Chauvenet M; Stroeymeyt K; Kaiserlian D; Drai J; Flourié B
Inflamm Bowel Dis; 2013 Apr; 19(5):1043-52. PubMed ID: 23511035
[TBL] [Abstract][Full Text] [Related]
6. Unfractioned heparin in the therapy of patients with highly active inflammatory bowel disease.
Folwaczny C; Wiebecke B; Loeschke K
Am J Gastroenterol; 1999 Jun; 94(6):1551-5. PubMed ID: 10364024
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of disease activity in IBD at the time of diagnosis by the use of clinical, biochemical, and fecal markers.
Ricanek P; Brackmann S; Perminow G; Lyckander LG; Sponheim J; Holme O; Høie O; Rydning A; Vatn MH;
Scand J Gastroenterol; 2011 Sep; 46(9):1081-91. PubMed ID: 21619483
[TBL] [Abstract][Full Text] [Related]
8. Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients.
Bodelier AG; Pierik MJ; van den Heuvel T; Bovee-Oudenhoven IM; de Boer E; Hameeteman W; Masclee AA; Jonkers D
Eur J Gastroenterol Hepatol; 2014 Aug; 26(8):902-9. PubMed ID: 24915490
[TBL] [Abstract][Full Text] [Related]
9. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices.
Langhorst J; Elsenbruch S; Koelzer J; Rueffer A; Michalsen A; Dobos GJ
Am J Gastroenterol; 2008 Jan; 103(1):162-9. PubMed ID: 17916108
[TBL] [Abstract][Full Text] [Related]
10. Fecal excretion of alpha 2-macroglobulin: a novel marker for disease activity in patients with inflammatory bowel disease.
Becker K; Niederau C; Frieling T
Z Gastroenterol; 1999 Jul; 37(7):597-605. PubMed ID: 10458008
[TBL] [Abstract][Full Text] [Related]
11. Platelet activating factor in stool from patients with ulcerative colitis and Crohn's disease.
Hocke M; Richter L; Bosseckert H; Eitner K
Hepatogastroenterology; 1999; 46(28):2333-7. PubMed ID: 10521992
[TBL] [Abstract][Full Text] [Related]
12. Individual fecal alpha 1-antitrypsin excretion reflects clinical activity in Crohn's disease but not in ulcerative colitis.
Becker K; Berger M; Niederau C; Frieling T
Hepatogastroenterology; 1999; 46(28):2309-14. PubMed ID: 10521988
[TBL] [Abstract][Full Text] [Related]
13. Altered subjective appetite parameters in Crohn's disease patients.
Bannerman E; Davidson I; Conway C; Culley D; Aldhous MC; Ghosh S
Clin Nutr; 2001 Oct; 20(5):399-405. PubMed ID: 11534934
[TBL] [Abstract][Full Text] [Related]
14. Autonomic cardiovascular regulation in quiescent ulcerative colitis and Crohn's disease.
Coruzzi P; Castiglioni P; Parati G; Brambilla V; Brambilla L; Gualerzi M; Cademartiri F; Franzè A; De Angelis G; Di Rienzo M; Di Mario F
Eur J Clin Invest; 2007 Dec; 37(12):964-70. PubMed ID: 18036030
[TBL] [Abstract][Full Text] [Related]
15. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis.
Niederau C; Backmerhoff F; Schumacher B; Niederau C
Hepatogastroenterology; 1997; 44(13):90-107. PubMed ID: 9058126
[TBL] [Abstract][Full Text] [Related]
16. Seroreactivity to E. coli outer membrane protein C antibodies in active inflammatory bowel disease; diagnostic value and correlation with phylogroup B2 E. coli infection.
Petersen AM; Schou C; Mirsepasi H; Engberg J; Friis-Møller A; Nordgaard-Lassen I; Wildt S; Krogfelt KA
Scand J Gastroenterol; 2012 Feb; 47(2):155-61. PubMed ID: 22150030
[TBL] [Abstract][Full Text] [Related]
17. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
18. [The usefulness of reactive protein C in managing patients with ulcerative colitis and Crohn's disease].
López Morante AJ; Sáez-Royuela F; Yuguero del Moral L; Martín Lorente JL; Ojeda Giménez C
Rev Esp Enferm Dig; 1993 Jan; 83(1):5-9. PubMed ID: 8452705
[TBL] [Abstract][Full Text] [Related]
19. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
20. Comparison of RANTES expression in Crohn's disease and ulcerative colitis: an aid in the differential diagnosis?
Ansari N; Abdulla J; Zayyani N; Brahmi U; Taha S; Satir AA
J Clin Pathol; 2006 Oct; 59(10):1066-72. PubMed ID: 16565224
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
